Kaplan and Sadocks Comprehensive Textbook of Psychiatry, 11e

xv

Contents

32.23 Other Methods of Psychotherapy Adam M. Brenner, M.D., and Aaron Van Wright, M.D. 32.24 Evaluating Psychotherapy: Research Methods, Findings, and Future Directions

33.5 Monoamine Enhancers (“Antidepressants”)

2974

3129 3129

33.5a Reuptake Inhibitors

33.5a.1 Serotonin Reuptake Inhibitors (SRIs)

3129

2987

Simon Lafrenière, M.D., M.Sc., and Pierre Blier, M.D., Ph.D.

Lindsay E. Holly, Ph.D., Megan L. Petrik, Ph.D., and Stephen M. Saunders, Ph.D.

33.5a.2 Serotonin-

33 BIOLOGIC THERAPIES

2995 2995

Norepinephrine Reuptake Inhibitors (SNRIs) 3144 Pierre Blier, M.D., Ph.D., and Michael E. Thase, M.D.

33.1 Preface

33.1a General Principles of Psychopharmacology

2995

Olusola Ajilore, M.D., Ph.D., and Mark M. Rasenick, Ph.D.

33.5a.3 Tricyclics and Tetracyclics

3151

33.1b Drug Development and Approval Process in the United States

J. Craig Nelson, M.D.

33.5a.4 Dopamine-

3017

Amir Kalali, M.D. 33.1c Classification of Psychotropics:

Noradrenaline Reuptake Inhibitors (Bupropion) Charles DeBattista, D.M.H., M.D., and Alan F. Schatzberg, M.D.

3163

Neuroscience-Based Nomenclature (NbN) 3026 Joseph Zohar, M.D., Sasson Zemach, M.D., and Daniel Minkin Levy, M.D.

33.5b 5HT 1A Receptor Partial Agonists (Buspirone)

33.2 Dopamine Blockers (“Antipsychotics”)

3168

3033 3033

Pierre Blier, M.D., Ph.D., and Cary Kogan, Ph.D., M.S.C.P. 33.5c Vilazodone and Vortioxetine ��� 3175 Pierre Blier, M.D., Ph.D., and Charles Desfossés, M.D. 33.5d Monoamine Oxidase Inhibitors 3184 Ethan F. Karsen, M.D., and Paul E. Holtzheimer, M.D., M.S.

33.2a Dopamine Antagonists

Martin T. Strassnig, M.D., and Philip D. Harvey, Ph.D.

33.2b Dopamine-Serotonin Antagonists

3054

Stephen R. Marder, M.D., and Walter Dunn, M.D., Ph.D.

33.2c Dopamine Blockers and

Neuromotor Adverse Effects ��� 3090 Philip G. Janicak, M.D., and Kumail Hussain, M.D.

33.6 Monoamine Modulators

3197 3197

33.6a Trazodone

John T. Vernon, M.D., and Susan G. Kornstein, M.D.

33.3 Dopamine Partial agonists

3100 3100

33.3a Dopamine Partial Agonists

33.6b Nefazodone

3204

Stephen R. Marder, M.D., and Walter Dunn, M.D., Ph.D.

Amir A. Khan, M.D., and Susan G. Kornstein, M.D.

33.4 Dopamine Enhancers

3106 33.4a Dopamine Receptor Agonists ��� 3106 Carlos A. Zarate, Jr., M.D., and Lawrence T. Park, A.M., M.D. 33.4b Amphetamines, Methylphenidate, Atomoxetine, and Modafinil ��� 3115 Manpreet Kaur Singh, M.D., M.S.

33.6c Mirtazapine

3211

Mousa Sobhy Azer Botros, M.D., Radu V. Saveanu, M.D., and Michael E. Thase, M.D.

Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of this content is prohibited.